Fate Therapeutics Created by Leading Stem Cell Scientists to Pursue New Approaches to Stem Cell Therapies
A group of the nation’s most respected leaders in stem cell biology today announced formation of Fate Therapeutics, a new biotechnology company developing drugs to control cell fate. Fate will harness the healing power of adult stem cells by using small molecule drugs to modulate cells in vivo (in the body) and by reprogramming mature adult cells into stem cells.
Article
San Diego Company Formed around Breakthrough in Embryonic Stem Cell Research
Cascade LifeSciences is the exclusive worldwide licensee of Dr. Mitalipov’s technology related to SCNT reprogramming as well as a second method of generating embryonic stem cells using an approach known as parthenogenesis.
Article
StemCells, Inc. Exploring Acquisition of Progenitor Cell Therapy, LLC
StemCells, Inc. today announced it is exploring the acquisition of privately held Progenitor Cell Therapy, LLC, a leading provider of cGMP-quality cell processing services headquartered in Hackensack, NJ.
Article
University of California, Los Angeles Scientists’ Biotech Firm to be Acquired by Pharmaceutical Corp.
Acquisition will make the faculty-founded company one of L.A.’s largest private biotechnology firms.
Article
Six Institutions to Focus on Stem Cells
Research institutions across Southern California have joined forces to advance stem cell research by establishing the Southern California Stem Cell Scientific Collaboration (SC3).
Article
Genzyme, French Firm Partner on Gene Therapies
Genzyme Corp. in Cambridge said on Tuesday that it hat signed a collaboration deal with Fovea Pharmaceuticals SA in Paris.
Article
Binex and MaxCyte Collaborate on Cancer Immunotherapy Research
Binex and MaxCyte, Inc. have announced the signing of a Sponsored Research Agreement to evaluate MaxCyte’s GMP-compliant cell loading technologyfor use in closed-system manufacturing of Binex’s cell-based cancer immunotherapies.
Article
Millipore Announces Collaboration with Abeome Corporation Partnership to Distribute Monoclonal Antibodies for Stem Cell Research
Millipore Corporation has announced its collaboration with Abeome Corporation on the development and distribution of a novel stem cell antibody. The antibody, Human Embryonic Stem Cell Antigen-1, is a previously unidentified marker for the analysis of pluripotent stem cells in immunocytochemistry and other immunological techniques.
Article
HepaLife(TM) Enters Into New Cooperative Research and Development Agreement with U.S. Government Agency
HepaLife Technologies, Inc. has announced that the Company has entered into a new Cooperative Research and Development Agreement with the U.S. Department of Agriculture, Agricultural Research Service for further optimization of HepaLife’s PICM-19 liver stem cell line for application in the first-of-its-kind bioartificial liver device.
Article
University of Texas at San Antonio Tapped for Army Contract to Develop Biomed Technologies
The University of Texas at San Antonio College of Engineering has been awarded a $2 million grant to develop bone-regeneration technologies for wounded soldiers.
Article
MicroIslet, Inc. Retains New York-Based Investor Relations Firm
MicroIslet, Inc. has engaged the Investor Relations Group, Inc., based in New York City, to serve as its new financial relations and corporate communications firm.
Article
Pluristem’s Reverse Stock Split Effective Today
Pluristem Therapeutics Inc. has announced that its previously disclosed two hundred for one reverse stock split has become effective. The Company’s name was also changed from Pluristem Life Systems, Inc. to Pluristem Therapeutics Inc.
Article
University of Pennsylvania Establishes Institute for Regenerative Medicine
The University of Pennsylvania is launching the Institute for Regenerative Medicine, a new cross-disciplinary endeavor to investigate and harness the therapeutic potential of stem cells in the treatment of cancer, diabetes, cardiovascular disease, degenerative diseases, wound healing and aging. Two renowned Penn scientists, Jonathan A. Epstein and Ralph L. Brinster, will lead the Institute.
Article
Regenerative Medicine Gets £10 Million Public Support
The UK’s Technology Strategy Board has committed £10 million to support collaborative research and development projects in the field of regenerative medicine.
Article
Arteriocyte Awarded $800,000 for Cellular Therapy for Battlefield Wounds Project as Part of Department of Defense Fiscal Year 2008 Budget
Arteriocyte has announced that the company will receive $800,000 for their Cellular Therapy for Battlefield Wounds project from the 2008 Defense Appropriations bill the President signed into law November 13th. U.S. Representative Stephanie Tubbs Jones and Senator Sherrod Brown championed the effort to secure the funding.
Article
Alnylam Announces Grant of Broad Patent Covering RNAi Therapeutics in Germany
Alnylam Pharmaceuticals, Inc. has announced that the German Patent Office has granted a patent (DE 10080167 or “’167 patent”) for the Kreutzer-Limmer I patent series.
Article